IFITM3 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

GO_0009615Biological processresponse to virus
GO_0006955Biological processimmune response
GO_0051607Biological processdefense response to virus
GO_0060337Biological processtype I interferon-mediated signaling pathway
GO_0035455Biological processresponse to interferon-alpha
GO_0045071Biological processnegative regulation of viral genome replication
GO_0034341Biological processresponse to type II interferon
GO_0046597Biological processnegative regulation of viral entry into host cell
GO_0035456Biological processresponse to interferon-beta
GO_0032897Biological processnegative regulation of viral transcription
GO_0031901Cellular componentearly endosome membrane
GO_0032991Cellular componentprotein-containing complex
GO_0031902Cellular componentlate endosome membrane
GO_0005886Cellular componentplasma membrane
GO_0005765Cellular componentlysosomal membrane
GO_0048471Cellular componentperinuclear region of cytoplasm
GO_0005515Molecular functionprotein binding

IV. Literature review

[source]
Gene nameIFITM3
Protein nameInterferon-induced transmembrane protein 3 (Dispanin subfamily A member 2b) (DSPA2b) (Interferon-inducible protein 1-8U)
Interferon induced transmembrane protein 3
IFITM3
Synonyms
DescriptionFUNCTION: IFN-induced antiviral protein which disrupts intracellular cholesterol homeostasis. Inhibits the entry of viruses to the host cell cytoplasm by preventing viral fusion with cholesterol depleted endosomes. May inactivate new enveloped viruses which buds out of the infected cell, by letting them go out with a cholesterol depleted membrane. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) . Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry . Plays a critical role in the structural stability and function of vacuolar ATPase (v-ATPase). Establishes physical contact with the v-ATPase of endosomes which is critical for proper clathrin localization and is also required for the function of the v-ATPase to lower the pH in phagocytic endosomes thus establishing an antiviral state. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation . IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome . Exerts opposing activities on SARS-CoV-2, including amphipathicity-dependent restriction of virus at endosomes and amphipathicity-independent enhancement of infection at the plasma membrane . .

AccessionsENST00000399808.5
ENST00000681840.1
ENST00000681198.1
ENST00000681748.1
ENST00000531688.2
A0A7P0T9S7
ENST00000680622.1
A0A7P0T8W2
A0A7P0TBF9
Q01628
A0A7P0TB46
ENST00000681184.1
H9NKY4
A0A7P0T9U8
ENST00000679441.1
ENST00000679433.1
E9PS44
ENST00000679382.1
R4GNG9
ENST00000680209.1
H9NL19
ENST00000679792.1
ENST00000681304.1
ENST00000602735.2
A0A7P0TB91
ENST00000680023.1
ENST00000680720.1
H9NL12
ENST00000526811.4